Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifying patients
2019-002470-32Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of hydroxychloroquine, leflunomide and mycophenolate mofetil in primary Sjögren's syndrome (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Primary efficacy (cohort-specific) and Primary efficacy (combined cohorts 1 and 2). Started Jul 2021; status: active.
02
Drugs
hydroxychloroquineleflunomidemycophenolate mofetil
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2019-002470-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002470-32.